Global Targeted PSMA Radionuclide Drug Conjugates Market Growth (Status and Outlook) 2026-2032
Description
The global Targeted PSMA Radionuclide Drug Conjugates market size is predicted to grow from US$ 1951 million in 2025 to US$ 3381 million in 2032; it is expected to grow at a CAGR of 7.9% from 2026 to 2032.
Targeted PSMA Radionuclide Drug Conjugates are precision radiotherapeutics designed to selectively deliver therapeutic radioisotopes to tumor tissue by targeting prostate-specific membrane antigen, or PSMA. These products are typically composed of a PSMA-targeting small molecule or ligand, a chelator, and a therapeutic radionuclide. Among current commercialized and clinical-stage products, 177Lu-labeled agents are the most mature, while alpha-emitting candidates such as 225Ac-based products are still largely in clinical development or early-stage application. This category is primarily used for the treatment of PSMA-positive advanced prostate cancer, especially metastatic castration-resistant prostate cancer, or mCRPC. Upstream segments mainly include targeting ligands and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of hospitals with nuclear medicine capabilities, cancer centers, specialty treatment networks, and radiopharmaceutical distribution systems. On a commercial-market basis, the global market in 2025 remained centered on Novartis’ Pluvicto, and the industry as a whole continued to show the characteristics of limited marketed products, an active clinical pipeline, and simultaneous technical and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized targeted PSMA radionuclide drug conjugates is estimated to be in the range of 55%-70%.
At present, the targeted PSMA radionuclide drug conjugate industry is in a stage driven by a limited number of commercialized products while accelerating into broader treatment settings. As the leading marketed products gradually move toward earlier lines of therapy, the sector is shifting from late-line clinical validation to a phase characterized by indication expansion and platform-based commercialization. This indicates that both the clinical value and commercial feasibility of the category are continuing to strengthen. Overall, market attention, capital investment, and pipeline activity are all increasing, and the industry is evolving from isolated product breakthroughs toward sustained competition centered on platform capability and indication expansion.
From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term because of its relatively mature clinical pathway, more established industrial infrastructure, and stronger commercialization foundation. At the same time, however, the industry is moving from competition around individual products to competition around platform capability. Future development is likely to focus not only on new ligand structures, combination regimens, and earlier treatment settings, but also on accelerated deployment of alpha-emitter approaches such as 225Ac in pursuit of stronger biological effects and differentiated therapeutic value. As leading companies continue to broaden their radioligand therapy portfolios, targeted PSMA drugs are likely to evolve from a single advanced prostate cancer therapy into a core component of broader radiopharmaceutical oncology platforms.
From an industrialization perspective, supply chain and manufacturing systems will be the key variables determining how quickly the industry can scale. Compared with conventional oncology drugs, targeted PSMA radionuclide drug conjugates place much higher demands on isotope supply, specialized manufacturing facilities, quality release, time-sensitive distribution, and hospital nuclear medicine capabilities. In the future, leading companies are expected to continue strengthening delivery resilience by expanding radiopharmaceutical production sites, building regional manufacturing networks, and increasing treatment-center coverage. As a result, competition will no longer be limited to the drug itself, but will increasingly become competition in integrated capabilities spanning product, manufacturing, logistics, and hospital access. In other words, companies that establish stable isotope access and strong treatment networks earlier will be better positioned in the commercialization phase.
Nevertheless, the industry still faces several constraints. Stable isotope supply, the construction cycle of dedicated capacity, and the availability of specialized treatment centers remain practical bottlenecks to market expansion. In addition, patient treatment pathways usually rely on PSMA imaging selection and supporting nuclear medicine infrastructure, while reimbursement systems, hospital access, and treatment standards differ significantly across countries and regions, making global market expansion uneven. As the category moves into earlier treatment settings and addresses a broader patient population, requirements for safety management, treatment standardization, and long-term follow-up data will also continue to rise. Overall, targeted PSMA radionuclide drug conjugates offer clear long-term growth potential, but future expansion is more likely to be gradual and system-driven, supported jointly by clinical evidence, supply assurance, and healthcare infrastructure development, rather than by rapid short-term scaling.
LPI (LP Information)' newest research report, the “Targeted PSMA Radionuclide Drug Conjugates Industry Forecast” looks at past sales and reviews total world Targeted PSMA Radionuclide Drug Conjugates sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted PSMA Radionuclide Drug Conjugates sales for 2026 through 2032. With Targeted PSMA Radionuclide Drug Conjugates sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted PSMA Radionuclide Drug Conjugates industry.
This Insight Report provides a comprehensive analysis of the global Targeted PSMA Radionuclide Drug Conjugates landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted PSMA Radionuclide Drug Conjugates portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted PSMA Radionuclide Drug Conjugates market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted PSMA Radionuclide Drug Conjugates and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted PSMA Radionuclide Drug Conjugates.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted PSMA Radionuclide Drug Conjugates market by product type, application, key players and key regions and countries.
Segmentation by Type:
Monotherapy Products
Combination Therapy Products
Segmentation by Radionuclide Type:
Beta-emitting
Alpha-emitting
Other
Segmentation by Targeting Vector Type:
Small-molecule
Antibody-based
Other
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Curium
Telix Pharmaceuticals
Lantheus
Fusion Pharmaceuticals
Blue Earth Therapeutics
Please note: The report will take approximately 2 business days to prepare and deliver.
Targeted PSMA Radionuclide Drug Conjugates are precision radiotherapeutics designed to selectively deliver therapeutic radioisotopes to tumor tissue by targeting prostate-specific membrane antigen, or PSMA. These products are typically composed of a PSMA-targeting small molecule or ligand, a chelator, and a therapeutic radionuclide. Among current commercialized and clinical-stage products, 177Lu-labeled agents are the most mature, while alpha-emitting candidates such as 225Ac-based products are still largely in clinical development or early-stage application. This category is primarily used for the treatment of PSMA-positive advanced prostate cancer, especially metastatic castration-resistant prostate cancer, or mCRPC. Upstream segments mainly include targeting ligands and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of hospitals with nuclear medicine capabilities, cancer centers, specialty treatment networks, and radiopharmaceutical distribution systems. On a commercial-market basis, the global market in 2025 remained centered on Novartis’ Pluvicto, and the industry as a whole continued to show the characteristics of limited marketed products, an active clinical pipeline, and simultaneous technical and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized targeted PSMA radionuclide drug conjugates is estimated to be in the range of 55%-70%.
At present, the targeted PSMA radionuclide drug conjugate industry is in a stage driven by a limited number of commercialized products while accelerating into broader treatment settings. As the leading marketed products gradually move toward earlier lines of therapy, the sector is shifting from late-line clinical validation to a phase characterized by indication expansion and platform-based commercialization. This indicates that both the clinical value and commercial feasibility of the category are continuing to strengthen. Overall, market attention, capital investment, and pipeline activity are all increasing, and the industry is evolving from isolated product breakthroughs toward sustained competition centered on platform capability and indication expansion.
From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term because of its relatively mature clinical pathway, more established industrial infrastructure, and stronger commercialization foundation. At the same time, however, the industry is moving from competition around individual products to competition around platform capability. Future development is likely to focus not only on new ligand structures, combination regimens, and earlier treatment settings, but also on accelerated deployment of alpha-emitter approaches such as 225Ac in pursuit of stronger biological effects and differentiated therapeutic value. As leading companies continue to broaden their radioligand therapy portfolios, targeted PSMA drugs are likely to evolve from a single advanced prostate cancer therapy into a core component of broader radiopharmaceutical oncology platforms.
From an industrialization perspective, supply chain and manufacturing systems will be the key variables determining how quickly the industry can scale. Compared with conventional oncology drugs, targeted PSMA radionuclide drug conjugates place much higher demands on isotope supply, specialized manufacturing facilities, quality release, time-sensitive distribution, and hospital nuclear medicine capabilities. In the future, leading companies are expected to continue strengthening delivery resilience by expanding radiopharmaceutical production sites, building regional manufacturing networks, and increasing treatment-center coverage. As a result, competition will no longer be limited to the drug itself, but will increasingly become competition in integrated capabilities spanning product, manufacturing, logistics, and hospital access. In other words, companies that establish stable isotope access and strong treatment networks earlier will be better positioned in the commercialization phase.
Nevertheless, the industry still faces several constraints. Stable isotope supply, the construction cycle of dedicated capacity, and the availability of specialized treatment centers remain practical bottlenecks to market expansion. In addition, patient treatment pathways usually rely on PSMA imaging selection and supporting nuclear medicine infrastructure, while reimbursement systems, hospital access, and treatment standards differ significantly across countries and regions, making global market expansion uneven. As the category moves into earlier treatment settings and addresses a broader patient population, requirements for safety management, treatment standardization, and long-term follow-up data will also continue to rise. Overall, targeted PSMA radionuclide drug conjugates offer clear long-term growth potential, but future expansion is more likely to be gradual and system-driven, supported jointly by clinical evidence, supply assurance, and healthcare infrastructure development, rather than by rapid short-term scaling.
LPI (LP Information)' newest research report, the “Targeted PSMA Radionuclide Drug Conjugates Industry Forecast” looks at past sales and reviews total world Targeted PSMA Radionuclide Drug Conjugates sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted PSMA Radionuclide Drug Conjugates sales for 2026 through 2032. With Targeted PSMA Radionuclide Drug Conjugates sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted PSMA Radionuclide Drug Conjugates industry.
This Insight Report provides a comprehensive analysis of the global Targeted PSMA Radionuclide Drug Conjugates landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted PSMA Radionuclide Drug Conjugates portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted PSMA Radionuclide Drug Conjugates market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted PSMA Radionuclide Drug Conjugates and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted PSMA Radionuclide Drug Conjugates.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted PSMA Radionuclide Drug Conjugates market by product type, application, key players and key regions and countries.
Segmentation by Type:
Monotherapy Products
Combination Therapy Products
Segmentation by Radionuclide Type:
Beta-emitting
Alpha-emitting
Other
Segmentation by Targeting Vector Type:
Small-molecule
Antibody-based
Other
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Curium
Telix Pharmaceuticals
Lantheus
Fusion Pharmaceuticals
Blue Earth Therapeutics
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
85 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Targeted PSMA Radionuclide Drug Conjugates Market Size by Player
- 4 Targeted PSMA Radionuclide Drug Conjugates by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Targeted PSMA Radionuclide Drug Conjugates Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
